Amid a pandemic, civil unrest and a divisive US election season, we now have an asteroid zooming toward us.
On the day before the presidential vote, no less.
Yep. The celestial object known as 2018VP1 is projected to come close to Earth on November 2, according to the Center for Near Earth Objects Studies at NASA’s Jet Propulsion Laboratory.
Electrification of transport has many faces and the automotive industry is exploring various paths to increase the share of electric miles in long-distance travel, but not necessarily by switching to full BEVs with huge batteries.
This summer, a new 5 km (3.1 mi) e-highway test track with catenary overhead lines (in both directions) entered service on the A5 Autobahn in Hessen, near Frankfurt in Germany. It’s part of a three-stage project announced in 2018.
Salk Institute scientists have harnessed stem cell technology to generate the first human insulin-producing pancreatic cell clusters that can evade the immune system. Generated from induced pluripotent stem cells (iPSCs), these “immune shielded” human islet-like organoids (HILOs) controlled blood glucose following transplantation into a mouse model of diabetes, without the use of immunosuppressive drugs. The researchers suggest the achievement represents a major advance in the quest for a safe and effective treatment for type 1 diabetes (T1D), which impacts an estimated 1.6 million people in the United States, at a cost of $14.4 billion annually.
“Most type 1 diabetics are children and teenagers,” said Salk professor Ronald Evans, PhD, holder of the March of Dimes chair in molecular and developmental biology. Evans is senior author of the team’s paper, which is published in Nature. “This is a disease that is historically hard to manage with drugs. We hope that regenerative medicine in combination with immune shielding can make a real difference in the field by replacing damaged cells with lab-generated human islet-like cell clusters that produce normal amounts of insulin on demand.”
The coronavirus has wreaked havoc on our world’s economy, and many scientists and nations are scrambling to get a vaccine out. In today’s video, I will talk about what will happen when that vaccine actually appears:
Normally, silence and secrecy are inherent in the spy business. For nine full years, Hulio never talked publicly about his billion-dollar hacking company—even when his hacking tools were linked to scandal or he was accused of being complicit in human rights abuses around the world. Lately, though, he’s speaking up.
“People don’t understand how intelligence works,” Hulio tells me over a video call from Tel Aviv. “It’s not easy. It’s not pleasant. Intelligence is a shitty business full of ethical dilemmas.”
